NNC 0070-0002 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses NNC 0070-0002 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses NNC 0070-0002 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy VolunteersTerminatedPhase 1Novo Nordisk A/SNCT01044108Written as NNC 0070-0002-0453
- Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female VolunteersTerminatedPhase 1Novo Nordisk A/SNCT00665665Written as NNC 0070-0002-0182
- Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese VolunteersWithdrawnPhase 1Novo Nordisk A/SNCT00728455Written as NNC 0070-0002-0349